PL4003317T3 - Askorbinian w zapobieganiu wystąpienia zwapnienia naczyń wywołanego przez statyny - Google Patents

Askorbinian w zapobieganiu wystąpienia zwapnienia naczyń wywołanego przez statyny

Info

Publication number: PL4003317T3
Authority: PL; Poland
Prior art keywords: ascorbate; prevention; vascular calcification; induced vascular; statin induced
Prior art date: 2019-07-29

Application number

PL20747478.4T

Other languages

English (en)

Inventor

Vadim Ivanov

Aleksandra Niedzwiecki

Matthias Rath

Original Assignee

Matthias Rath

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-07-29

Filing date

2020-07-27

Publication date

2024-03-04

2019-07-29 Priority claimed from US16/524,383 external-priority patent/US11547693B2/en

2020-07-27 Application filed by Matthias Rath filed Critical Matthias Rath

2024-03-04 Publication of PL4003317T3 publication Critical patent/PL4003317T3/pl

Links

CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
208000005475 Vascular calcification Diseases 0.000 title 1
229940072107 ascorbate Drugs 0.000 title 1
235000010323 ascorbic acid Nutrition 0.000 title 1
239000011668 ascorbic acid Substances 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL20747478.4T 2019-07-29 2020-07-27 Askorbinian w zapobieganiu wystąpienia zwapnienia naczyń wywołanego przez statyny PL4003317T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US16/524,383 US11547693B2 (en)	2019-07-29	2019-07-29	Ascorbate in the prevention of statin induced vascular calcification
EP19190436		2019-08-07
US201916562313A	2019-09-05	2019-09-05
PCT/IB2020/057063 WO2021019421A2 (en)	2019-07-29	2020-07-27	Ascorbate in the prevention of statin induced vascular calcification

Publications (1)

Publication Number	Publication Date
PL4003317T3 true PL4003317T3 (pl)	2024-03-04

Family

ID=71846427

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL20747478.4T PL4003317T3 (pl)	2019-07-29	2020-07-27	Askorbinian w zapobieganiu wystąpienia zwapnienia naczyń wywołanego przez statyny

Country Status (9)

Country	Link
EP (2)	EP4279129A3 (pl)
JP (1)	JP2022543049A (pl)
KR (1)	KR20220041879A (pl)
AU (1)	AU2020322231A1 (pl)
BR (1)	BR112022001422A2 (pl)
CA (1)	CA3145041A1 (pl)
ES (1)	ES2965346T3 (pl)
PL (1)	PL4003317T3 (pl)
WO (1)	WO2021019421A2 (pl)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0347864A3 (en) *	1988-06-24	1992-04-01	Andries Johannes Cornelus Strydom	Anti-atherogenic agents
US4929437A (en)	1989-02-02	1990-05-29	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US7037934B2 (en) *	2000-12-14	2006-05-02	Sankyo Company, Limited	Blood lipid ameliorant composition
AU2002221131A1 (en) *	2000-12-14	2002-06-24	Sankyo Company Limited	Blood lipid ameliorant composition
EP1214893A1 (en) *	2000-12-16	2002-06-19	Aventis Pharma Deutschland GmbH	Health promoting compositions
TWI284529B (en) *	2000-12-18	2007-08-01	Sankyo Co	A composition for lowering triglyceride
ES2192988B1 (es) *	2002-02-28	2005-02-16	Jose Manuel Quesada Gomez	Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
US7034012B2 (en) *	2002-11-01	2006-04-25	Matthias Rath	Composition and method for prevention and treatment of arrhythmias
JP4880685B2 (ja) *	2005-07-22	2012-02-22	ザプロクターアンドギャンブルカンパニー	薬物による不整脈の発生を低減するための組成物
US20070265211A1 (en) *	2006-05-12	2007-11-15	Matthias Rath	Novel composition and method effective in inhibiting the atherogenic process
US8911798B2 (en) *	2007-09-17	2014-12-16	Ajay Gupta	Multivitamin and mineral compositions for individuals having renal disease
US20100021573A1 (en) *	2008-07-22	2010-01-28	Michael J Gonzalez	Compositions and methods for the prevention of cardiovascular disease
JP6053945B2 (ja) *	2012-11-23	2016-12-27	ペキンユニバーシティサードホスピタルＰｅｋｉｎｇＵｎｉｖｅｒｓｉｔｙＴｈｉｒｄＨｏｓｐｉｔａｌ	肥満症、糖尿病、高血圧症及び高脂血症を治療するための局所薬としてのスタチン化合物の使用
US20170348280A1 (en) *	2016-06-06	2017-12-07	Matthias W Rath	Counteracting the inhibition of collagen synthesis by select calcium and sodium channel blockers using ascorbic acid and ascorbyl palmitate

2020
- 2020-07-27 BR BR112022001422A patent/BR112022001422A2/pt not_active Application Discontinuation
- 2020-07-27 WO PCT/IB2020/057063 patent/WO2021019421A2/en not_active Ceased
- 2020-07-27 EP EP23198312.3A patent/EP4279129A3/en active Pending
- 2020-07-27 JP JP2022506423A patent/JP2022543049A/ja active Pending
- 2020-07-27 CA CA3145041A patent/CA3145041A1/en active Pending
- 2020-07-27 ES ES20747478T patent/ES2965346T3/es active Active
- 2020-07-27 KR KR1020227006588A patent/KR20220041879A/ko not_active Withdrawn
- 2020-07-27 EP EP20747478.4A patent/EP4003317B1/en active Active
- 2020-07-27 PL PL20747478.4T patent/PL4003317T3/pl unknown
- 2020-07-27 AU AU2020322231A patent/AU2020322231A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2022543049A (ja)	2022-10-07
EP4003317B1 (en)	2023-09-20
CA3145041A1 (en)	2021-02-04
EP4279129A3 (en)	2024-05-29
EP4279129A2 (en)	2023-11-22
WO2021019421A2 (en)	2021-02-04
WO2021019421A3 (en)	2021-03-25
BR112022001422A2 (pt)	2022-03-22
AU2020322231A1 (en)	2022-02-24
ES2965346T3 (es)	2024-04-12
EP4003317A2 (en)	2022-06-01
KR20220041879A (ko)	2022-04-01

Publication	Publication Date	Title
HUE069999T2 (hu)	2025-04-28	Kompozíció miópia megelõzésében vagy szuppressziójában történõ alkalmazásra
IL292296B1 (en)	2025-03-01	Inhibition of human integrin a4B7
SMT202300272T1 (it)	2023-09-06	Terapia di combinazione per il trattamento o prevenzione di tumori
IL279347A (en)	2021-01-31	Gremlin-1 antagonist for cancer prevention and treatment
IL290656A (en)	2022-04-01	Lorbinectadine in the treatment of malignant mesothelioma
GB201820450D0 (en)	2019-01-30	Compound and its use for the treatment of alpha1-antitryspin deficiency
SG11202012070YA (en)	2021-01-28	Methods and compositions for preventing or treating tissue calcification
IL268502A (en)	2019-09-26	Triple combination preparations and methods for treating heart disease or reducing its risk
SG11202107720UA (en)	2021-08-30	Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
CA188496S (en)	2021-02-05	Combination eyewash and faucet
ZA202207493B (en)	2023-12-20	Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HUE063053T2 (hu)	2023-12-28	IDHP vérlemezke-aggregáció terápiás gátlásában, angiogenezis terápiás célú elõsegítésében és vaszkuláris demencia megelõzésében vagy kezelésében való alkalmazásra
IL280218A (en)	2021-03-01	Methods for the treatment of HFPEF using dapagliflozin and compounds containing it
GB201918413D0 (en)	2020-01-29	Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en)	2020-01-29	Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
PL4003317T3 (pl)	2024-03-04	Askorbinian w zapobieganiu wystąpienia zwapnienia naczyń wywołanego przez statyny
GB201918404D0 (en)	2020-01-29	Compounds and their use for the treatment of aplha1-antitrypsin deficiency
PT3737378T (pt)	2023-05-23	Palonossetrom para o tratamento ou prevenção de náusea e vómito
SMT202400167T1 (it)	2024-07-09	Composizione per la prevenzione e il trattamento dei danni alla pelle causati da fotoesposizione
IL285593A (en)	2021-09-30	Compounds and compositions containing them for the treatment of hypertension or heart failure
WO2016038040A3 (en)	2016-07-14	Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation
KR102373488B9 (ko)	2022-12-08	면역활성 또는 암의 예방 또는 치료용 의약 조성물
IL271564A (en)	2020-02-27	Preparations for the prevention and treatment of severe kidney damage
GB201918416D0 (en)	2020-01-29	Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201914142D0 (en)	2019-11-13	Treatment and prevention of vascular calcification